Lixte Biotech Advances Precision Oncology with LB-100 and Liora Technologies Partnership
Lixte Biotech Holdings (NASDAQ: LIXT) is making significant strides in the realm of precision oncology through the development of LB-100, a first-in-class therapy aimed at enhancing the effectiveness of established…